Other novel therapies include glucokinase activators (GKAs) such as dorzagliatin, which fully activate glucokinase by stabilizing its active conformation, thereby improving β-cell performance, reducing insulin resistance, and restoring glycemic control in T2DM [134]. Here, GCK is linked to type 2 diabetes mellitus.